Literature DB >> 2989316

Diurnal variation in the response of plasma adrenocorticotropin and cortisol to intravenous ovine corticotropin-releasing hormone.

G S DeCherney, C R DeBold, R V Jackson, W R Sheldon, D P Island, D N Orth.   

Abstract

To determine whether the plasma immunoreactive ACTH (IR-ACTH) and IR-cortisol responses to ovine corticotropin-releasing hormone (oCRH) depend on the time of day, we administered 1 microgram/kg BW synthetic oCRH as an iv bolus dose to five normal men at their usual time of awakening between 0530-0740 h, at 1600 h, and at 2300 h. Mean basal plasma IR-ACTH and IR-cortisol levels were highest upon awakening, intermediate at 1600 h, and lowest at 2300 h, reflecting the diurnal rhythm of ACTH secretion. There was no significant difference in the plasma IR-ACTH response to oCRH at different times of the day. In contrast, the mean maximum plasma IR-cortisol increment and mean integrated response were 2- and 2.6-fold greater (P less than 0.05), respectively, at 2300 h than upon awakening. In another study, oCRH was given in the morning (0700-0900 h) to 22 normal men and in the late afternoon (1600-1800 h) to 24 normal men. Mean basal plasma IR-ACTH and IR-cortisol levels were significantly higher (P less than 0.001) in the morning [24 +/- 3 pg/ml (mean +/- SEM) and 10.6 +/- 0.8 micrograms/dl, respectively] than in the afternoon (13 +/- 2 pg/ml and 5.6 +/- 0.6 micrograms/dl, respectively). Mean peak plasma IR-ACTH was slightly greater in the morning (60 +/- 5.5 pg/ml) than in the afternoon (47 +/- 5.5 pg/ml), the mean maximum plasma IR-ACTH increments were the same (35 +/- 4 and 34 +/- 5 pg/ml, respectively), and the mean integrated IR-ACTH response was slightly less in the morning (2036 +/- 414 vs. 2365 +/- 358 pg . min/ml), but none of these differences was statistically significant. Mean peak plasma IR-cortisol concentrations in the morning and afternoon were similar (18.7 +/- 0.7 and 17.3 +/- 0.9 micrograms/dl, respectively), but the mean maximum plasma IR-cortisol increments (8.1 +/- 0.8 and 11.7 +/- 0.9 micrograms/dl, respectively; P less than 0.005), and the mean integrated IR-cortisol responses (588 +/- 115 and 976 +/- 95 micrograms . min/dl, respectively; P less than 0.01) were greater in the afternoon. There was an inverse correlation between basal plasma IR-cortisol concentration and the integrated IR-ACTH response (P less than 0.05), the maximum IR-cortisol increment (P less than 0.001), and the integrated IR-cortisol response (P less than 0.001).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989316     DOI: 10.1210/jcem-61-2-273

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Safety and side effects of human and ovine corticotropin-releasing hormone administration in man.

Authors:  M Nink; U Krause; H Lehnert; J Beyer
Journal:  Klin Wochenschr       Date:  1991-03-18

Review 2.  The emerging role of peripheral corticotropin-releasing hormone (CRH).

Authors:  I Ilias; G Mastorakos
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

3.  Intra- and extracerebral blood flow changes and flushing after intravenous injection of human corticotropin-releasing hormone.

Authors:  A Kübler; G Rothacher; V A Knappertz; G Krämer; M Nink; J Beyer; H Lehnert
Journal:  Clin Investig       Date:  1994-05

4.  Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH.

Authors:  R A Salata; D B Jarrett; J G Verbalis; A G Robinson
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

5.  RELIABILITY OF THE CORTICOTROPIN RELEASING HORMONE STIMULATION TEST FOR DIFFERENTIATING BETWEEN ACTH DEPENDENT AND INDEPENDENT CUSHING SYNDROME.

Authors:  O Polat Korkmaz; B Karayel; M Korkmaz; O Haliloglu; S Sahin; E Durcan; M M Oren; P Kadioglu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.